Phacilitate WEBINAR SERIES: Funding, Commercialisation and Market Access for Advanced Therapies

WEBINAR SERIES: Funding, Commercialisation and Market Access for Advanced Therapies

This webinar series has been co-organised by Phacilitate and Biotech and Money/LSX

Welcome to the three-part webinar series dedicated to the funding, commercialisation and market access for advanced therapies. It is designed to take you through the advanced therapies journey addressing the main barriers to commercialisation along the way and solutions to get treatments to the patients that need them.

You can register for one, two or all three webinars.

 

Part One April 19th, 2018: Funding sources for advanced therapies

The first webinar examines the various funding sources for the advanced therapies industry, providing a guide to ensuring you secure the right capital for long-term, sustainable growth. World-leading experts from Credit Suisse, 4BIO and INKEF Capital will be sharing their experience, including advice on how to position yourself as an attractive investment opportunity.

This session will discuss:

  • Understanding the various funding sources and when to access them
  • Ensuring access to capital for long-term growth
  • How to position yourself as an attractive investment opportunity

Moderator: Vamil Divan, Analyst, Credit Suisse

Speaker: Dmitry Kuzmin, Managing Partner, 4BIO Capital

Speaker: Lucas de Breed, Director, INKEF Capital

Phacilitate webinar series 2018


 

Part Two May 22nd, 2018: Overcoming the scale-up challenge and the role of tech innovation and financing in overcoming these barriers to commercialisation

The second session tackles the scale-up challenge faced en masse by our industry. You will focus on solutions to overcome barriers to commercialisation of advanced therapies, including the role of tech innovation and financing where Rodney Rietze, Senior Investigator, Exploratory Immuno-Oncology group at Novartis Institute for Biomedical Research will be sharing his extensive automation experience. Rodney will also provide a framework to ensure your capital investment in automation technology delivers the anticipated ROI.

This session will discuss:

  • How does scale-up impede commercialisation of advanced therapies?
  • Understanding automation and the lifecycle of an automation project
  • Developing a robust automation strategy; when and where do you begin? 
  • Ensuring your capital delivers the anticipated return on investment (ROI)
  • The impact that the right investor partner can have on commercialisation

Speaker: Rodney Rietze, Senior Investigator, Exploratory Immuno-Oncology group at Novartis Institute for Biomedical Research

Speaker: Ron Philip, Head of Global Commercial, Spark Therapeutics

Phacilitate webinar series part two 2018


 

Part Three June 26th, 2018: Gaining market access in a challenging European environment

The final webinar completes the commercialisation story, homing in on gaining market access in a challenging European environment, as well as how to price your product and the lessons learnt from other pricing strategies.

This session will discuss:

  • Pricing and reimbursement: costs don’t equate to market value, how to price your product
  • The HTA’s perspective on reimbursement

Phacilitate webinar series part three 2018